Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Chaudfontaine – page 6

1 393 clinical trials in Chaudfontaine, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaudfontaine at a glance
1 393
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 393 trials in Chaudfontaine

Open in trial search

Testing inotuzumab ozogamicin and blinatumomab with drug combination for children with relapsed precursor B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

A Study of SAB-142 to Slow the Progression of Type 1 Diabetes in Adults and Children Recently Diagnosed with the Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Sab Biotherapeutics Inc.

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on Golcadomide for Patients with Relapsed or Refractory Large B-Cell Lymphoma in the Brain

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Comparing 18F-FDG and 68Ga-FAPI-46 for PET Scans in Patients with Hormone-Positive Breast Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:68Ga-FAPI-46
  • Sponsor:University Hospital Maastricht

Study on Bortezomib and Drug Combination for Children with High-Risk Relapsed Acute Lymphoblastic Leukemia (ALL)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study on the Effects of Baricitinib and Drug Combination for Adults with Severe Community-Acquired Pneumonia, Severe Influenza, or Severe and Moderate COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amoxicillin Sodium
  • Sponsor:Universitair Medisch Centrum Utrecht

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Prostate cancer

Recruiting

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Novartis Pharma AG

Study Comparing Clindamycin to Rifampicin and Drug Combination for Patients with Prosthetic Joint Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Clindamycin
  • Sponsor:Leids Universitair Medisch Centrum (LUMC)

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Chaudfontaine

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. The research examines alternative approaches for managing functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Alternative Treatment Strategies

The study explores on-demand medication protocols and alternative therapeutic options, including alginate formulations, to improve patient care in primary healthcare settings.

02 Primary Care Innovation

Research evaluating optimal medication management strategies for patients with heartburn and reflux conditions. The study aims to establish evidence-based approaches for reducing long-term medication dependence.

  • Medication Optimization
  • Patient-Centered Care
  • Treatment Effectiveness

This investigation compares different therapeutic approaches to help healthcare providers make informed decisions about long-term medication management.

03 Therapeutic Management

A comprehensive evaluation of deprescribing strategies in primary care, comparing traditional dose reduction methods with innovative approaches to medication management.

  • Clinical Effectiveness
  • Patient Safety
  • Quality of Care

The research focuses on developing evidence-based protocols for transitioning patients from long-term medication use to more appropriate treatment regimens.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.